In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview with Lifestyle Forum, Chairman Tse-Wen Chang highlighted the innovative drug design of TE-8214 and its potential breakthrough applications in clinical settings. Looking ahead to 2026, Immunwork will initiate the next phases of clinical trials for […]
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), TE-8105, developed for the treatment of obesity. Conducted in Australia, the study demonstrated that TE-8105 is safe, well tolerated, and exhibits clear weight-loss potential, with only mild adverse
T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of only six companies worldwide to be shortlisted for the “Best New Drug Developer 2025” category at the 12th World ADC Awards. This recognition highlights T-E Meds’ outstanding achievements in ADC technology platforms and innovative drug
T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category at the 12th World ADC Awards 2025. Selected from a highly competitive pool of global nominees, T-E Meds is one of six finalists to receive this distinguished honor. Since its launch in 2014, the World
T-E Meds Shortlisted for World ADC Awards – Best New Drug Developer Read More »
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection site reactions seen with current therapies.• Strong Pharmacodynamic Activity: Robust, dose-dependent reduction of disease biomarker IGF-1, with 83% of high-dose participants achieving a >20% reduction, confirming therapeutic potential.• Significant Market Potential: Positioned for the US$10 billion long-acting
On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning of a deep strategic collaboration in the field of innovative drug development, with the goal of jointly advancing the global pharmaceutical industry.Ms. Yang Rui, Co-CEO of Asymchem, and Dr. Hsin-Mao Chu, CEO of T-E Meds,
Website link: https://news.gbimonthly.com/tw/article/show.php?num=75729&page=1
Great News! Immunwork’s Latest Publication Offers a Promising Clinical Solution for Diabetes, Obesity, and NASH Disease! The study, titled “2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide,” has been published in the prestigious Journal of Medicinal Chemistry. Led by Dr. Wun-Teng Wong, Manager of
Our latest research result is published in J. Med. Chem. Read More »
Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th January. Immunwork has developed two ultra-long-acting drugs: TE-8105 and TE-8214. TE-8105 primarily targets type 2 diabetes, obesity, and fatty liver disease, and is scheduled to complete Phase 2a clinical trials this year. TE-8214 focuses on
Immunwork 2025 Investor Meeting – Results Presentation Read More »
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to the contract, T-E Meds will receive a signing and licensing fee of NT$270 million (approximately USD 8.5 million) for granting the commercialization rights of the TE-1146 drug in Taiwan, Southeast Asia, New Zealand and the
T-E Meds and Orient EuroPharma Forge Licensing Agreement for TE-1146 Read More »
